Importantly, CRISPR-SKIP also has multiple potential applications in biomedicine, given that exon skipping strategies have already shown promise for treating several monogenic diseases, such as Leber congenital amaurosis [26], atherosclerosis [27], FTDP-17 [28], cancer [29], rheumatoid arthritis [30], Huntington’s disease [17], dystrophic epidermis bullosa [31], and Duchenne muscular dystrophy (DMD) [32]. This evidence concerns the gene MAPT and Leber congenital amaurosis.